Development of Cyclobutene‐ and Cyclobutane‐Functionalized Fatty Acids with Inhibitory Activity against Mycobacterium tuberculosis

Eleven fatty acid analogues incorporating four‐membered carbocycles (cyclobutenes, cyclobutanes, cyclobutanones, and cyclobutanols) were investigated for the ability to inhibit the growth of Mycobacterium smegmatis (Msm) and Mycobacterium tuberculosis (Mtb). A number of the analogues displayed inhibitory activity against both mycobacterial species in minimal media. Several of the molecules displayed potent levels of inhibition against Mtb, with MIC values equal to or below those observed with the anti‐tuberculosis drugs D‐cycloserine and isoniazid. In contrast, two of the analogues that display the greatest activity against Mtb failed to inhibit E. coli growth under either set of conditions. Thus, the active molecules identified herein may provide the basis for the development of anti‐mycobacterial agents against Mtb.

[1]  K. Floyd,et al.  Scaling up interventions to achieve global tuberculosis control: progress and new developments , 2012, The Lancet.

[2]  Eric Arnoult,et al.  The challenge of new drug discovery for tuberculosis , 2011, Nature.

[3]  A. Greene,et al.  Asymmetric synthesis of functionalized, monocyclic chlorocyclobutenes. , 2010, Organic letters.

[4]  M. Glickman,et al.  Mycolic acid cyclopropanation is essential for viability, drug resistance, and cell wall integrity of Mycobacterium tuberculosis. , 2009, Chemistry & biology.

[5]  Gibson S. Kibiki,et al.  New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development , 2008, Antimicrobial Agents and Chemotherapy.

[6]  A. Greene,et al.  Expedient approach to chiral cyclobutanones: asymmetric synthesis of cyclobut-G. , 2008, Organic letters.

[7]  J. Baldwin,et al.  Thermal chemistry of bicyclo[4.2.0]oct-2-enes. , 2007, The Journal of organic chemistry.

[8]  R. Curi,et al.  Comparative toxicity of fatty acids on a macrophage cell line (J774). , 2006, Clinical science.

[9]  James C Sacchettini,et al.  Dual inhibition of mycobacterial fatty acid biosynthesis and degradation by 2-alkynoic acids. , 2006, Chemistry & biology.

[10]  Z. Paryzek,et al.  Abnormal Beckmann rearrangement of steroidal α-chlorocyclobutanone oximes: the fragmentation–substitution reaction , 2006 .

[11]  Marc Strous,et al.  Structural identification of ladderane and other membrane lipids of planctomycetes capable of anaerobic ammonium oxidation (anammox) , 2005, The FEBS journal.

[12]  Robert A. Field,et al.  New Small-Molecule Synthetic Antimycobacterials , 2005, Antimicrobial Agents and Chemotherapy.

[13]  G. Besra,et al.  Pathway to Synthesis and Processing of Mycolic Acids in Mycobacterium tuberculosis , 2005, Clinical Microbiology Reviews.

[14]  B. Shoichet,et al.  Identification and prediction of promiscuous aggregating inhibitors among known drugs. , 2003, Journal of medicinal chemistry.

[15]  B. Shoichet,et al.  A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.

[16]  C. Locht,et al.  Inhibition of InhA Activity, but Not KasA Activity, Induces Formation of a KasA-containing Complex in Mycobacteria* , 2003, Journal of Biological Chemistry.

[17]  Adri C. T. van Duin,et al.  Linearly concatenated cyclobutane lipids form a dense bacterial membrane , 2002, Nature.

[18]  David A. Bak,et al.  Halogenated ketenes. 31. Cycloaddition of dichloroketene with hindered olefins , 2002 .

[19]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[20]  N. B. Harris,et al.  Mycobacterium smegmatis d-Alanine Racemase Mutants Are Not Dependent on d-Alanine for Growth , 2002, Antimicrobial Agents and Chemotherapy.

[21]  G. Rishton.  Reactive compounds and in vitro false positives in HTS , 1997 .

[22]  D. Minnikin,et al.  Stimulation of mycolic acid biosynthesis by incorporation of cis-tetracos-5-enoic acid in a cell-wall preparation from Mycobacterium smegmatis. , 1993, Biochimica et biophysica acta.

[23]  S. Cole,et al.  The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis , 1992, Nature.

[24]  T. Kaneda,et al.  Iso- and anteiso-fatty acids in bacteria: biosynthesis, function, and taxonomic significance. , 1991, Microbiological reviews.

[25]  K. Belfield,et al.  Specifically deuteriated bicyclo[3.2.0]hepta-2,6-dienes , 1987 .

[26]  F. Coelho,et al.  A simple procedure for stereospecific vicinal dicarboxylation of olefins , 1985 .

[27]  S. Larson,et al.  Radiometric measurement of differential metabolism of fatty acid by mycobacteria. , 1982, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[28]  A. Greene,et al.  A versatile three-carbon annelation. Synthesis of cyclopentanones and cyclopentanone derivatives from olefins , 1979 .

[29]  L. R. Krepski,et al.  Cycloadditions. 24. An improved procedure for the addition of dichloroketene to unreactive olefins , 1978 .

[30]  K. Poralla,et al.  Synthesis of omega-alicyclic fatty acids from cyclic precursors in Bacillus subtilis , 1976, Journal of bacteriology.

[31]  W. T. Brady,et al.  Halogenated ketenes. V. Cycloadditions of dichloroketene to olefins , 1967 .

[32]  R. Dubos,et al.  THE BINDING OF FATTY ACIDS BY SERUM ALBUMIN, A PROTECTIVE GROWTH FACTOR IN BACTERIOLOGICAL MEDIA , 1947, The Journal of experimental medicine.

[33]  N. Carballeira.  New advances in fatty acids as antimalarial, antimycobacterial and antifungal agents. , 2008, Progress in lipid research.

[34]  Ying Zhang,et al.  The magic bullets and tuberculosis drug targets. , 2005, Annual review of pharmacology and toxicology.

[35]  B. Moore,et al.  1.03 – Biosynthesis of Cyclic Fatty Acids Containing Cyclopropyl-, Cyclopentyl-, Cyclohexyl-, and Cycloheptyl-rings , 1999 .

[36]  H. Frey,et al.  Thermal unimolecular isomerizations of substituted cyclobutenes. Part 4.—1,3-Dimethylcyclobutene and 1,4-dimethylcyclobutene , 1965 .